Pregnancy associated plasma protein A: An indicator of adverse obstetric outcomes in a South India population

Shah, Krupa H; Anjum, Afsha; Nair, P N Radhakrishnan; Bhat, Parvati; Bhat, Rani Akhil; Bhat, Seetharama M

doi:10.4274/tjod.galenos.2020.05695

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging evidence suggests that low PAPP-A levels are associated with fetal rejection, compromised placentation, and a range of complications including spontaneous abortion, preterm delivery, fetal growth restriction, preeclampsia, and stillbirth. The influential FASTER trial found that PAPP-A levels below the 5th percentile were linked to an increased risk of fetal growth restriction, spontaneous abortions, preterm delivery, low birth weight, preeclampsia, and placental abruption, and these results were consistent with findings from other studies (6,8).…”

Section: Introductionsupporting

confidence: 85%

“…Additionally, IGF regulates the uptake of glucose and amino acids, thereby influencing fetal growth. Thus, PAPP-A is involved in the regulation of IGF activity (5)(6)(7). Emerging evidence suggests that low PAPP-A levels are associated with fetal rejection, compromised placentation, and a range of complications including spontaneous abortion, preterm delivery, fetal growth restriction, preeclampsia, and stillbirth.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy-Associated Plasma Protein-A: Its Significance as a Single Biomarker for Adverse Obstetric Outcomes

Dey,

Choudhury,

Chawla

et al. 2023

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

OBJECTIVES: Low levels of pregnancy-associated plasma protein-A in pregnant women linked to unhealthy placentation and a spectrum of maternal and fetal complications. Its assessment as a single biomarker has the potential to identify high-risk pregnancies. This prospective observational study was conducted to find a correlation between low pregnancy-associated plasma protein-A levels in the first trimester of pregnancy with various obstetric outcomes to establish if it can be used as a single biomarker for counseling couples. STUDY DESIGN: The study was conducted at Base Hospital, Delhi Cantt. Maternal serum pregnancy-associated plasma protein-A levels were assessed at 11 to 13+6 weeks of gestation, converted in multiples of the median and patients were followed till delivery. Maternal outcomes were recorded in terms of abortions, development of gestational hypertension, gestational diabetes, preeclampsia, placental abruption, fetal growth restriction, fetal demise, neonatal intensive care unit admission, etc., and analyzed to find an association with levels first trimester of pregnancy-associated plasma protein-A. RESULTS: Low pregnancy-associated plasma protein-A levels showed a statistically significant association with gestational hypertension, preeclampsia, abortion, fetal demise, and also for adverse neonatal outcomes like APGAR <5 at 1 min, fetal growth restriction, neonatal intensive care unit admission, and perinatal deaths. No significant association was observed for preterm delivery, gestational diabetes, and placental abruption. CONCLUSION: Serum pregnancy-associated plasma protein-A levels in the first trimester of pregnancy have the potential of being utilized as a validated marker for adverse pregnancy outcomes. Early identification of such pregnancies can help in optimizing feto-maternal outcomes through closer surveillance, timely intervention, and referral to tertiary care centers. Further research would help the fraternity in developing a prediction model.

show abstract

Section: Introductionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Pregnancy-Associated Plasma Protein-A: Its Significance as a Single Biomarker for Adverse Obstetric Outcomes

Dey,

Choudhury,

Chawla

et al. 2023

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

show abstract

“…Based on our results, the highest association of low level PAPP-A was seen with IUGR. In this context, other reports have shown IUGR to be more associated with low maternal serum PAPP-A ( 20 , 21 ). Only in one research no association between low level PAPP-A and IUGR is reported ( 22 ).…”

Section: Discussionmentioning

confidence: 76%

High Frequency of Fetal Loss in Fetuses with Normal Karyotype and Nuchal Translucency ≥ 3 among the Iranian Pregnant Women

Abotorabi

Moghbelinejad

2020

JFRH

View full text Add to dashboard Cite

Objective: The purpose of this study was comparison of association of three main first trimester screening factors with pregnancy outcomes among Iranian pregnant women. Materials and methods: This prospective study was done during 2017-2019 years in Qazvin, Iran. To do so, a total of 1500pregnant women in first trimester were enrolled. At the first step, Nuchal translucency (NT) was measured in 11-13 ± 5 week, then the serum pregnancy-associated plasma protein A (PAPP-A) and free-β-human chorionic gonadotropin (free-β-HCG) were measured in 12-14 weeks of gestation. Pregnant women were followed up until the end of pregnancy for the complications of pregnancy such as intra-uterine growth retardation (IUGR), intrauterine death (IUFD), different types of fetal loss and preterm labor. Results: The results showed that low levels of serum biomarkers had more association with pregnancy complications in comparison to high levels of them. Significant association of IUGR (P = 0.001), IUFD (P = 0.032) and pre-term labor (P = 0.002) was shown in women with low serum levels of PAPP-A in comparison to low serum levels of free-β-hCG. Significant high frequency of different types of fetal loss (IUFD, Abortion, Elective termination) was shown in fetuses with N ≥ 3 in comparison to low levels of serum biomarkers (P = 0.001). Conclusion: This study highlighted the importance of accurately interpreting the results of the first trimester of pregnancy screening which should be considered by primatologists for subsequent pregnancy care.

show abstract

“…It appears in circulation after blastocyst implantation. A low serum concentration of PAPP-A after 24 weeks of pregnancy is significantly correlated with placental dysfunction, stillbirth, PTB, intrauterine or fetal growth restriction, and fetal death [71]. The neuropeptide urocortin, produced by amnion and chorion, encourages prostaglandin-mediated delivery through uterine contraction.…”

Section: Proteomic Biomarkersmentioning

confidence: 99%

Recent Advances and Challenges in the Early Diagnosis and Treatment of Preterm Labor

Gondane,

Kumbhakarn,

Maity

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Preterm birth (PTB) is the primary cause of neonatal mortality and long-term disabilities. The unknown mechanism behind PTB makes diagnosis difficult, yet early detection is necessary for controlling and averting related consequences. The primary focus of this work is to provide an overview of the known risk factors associated with preterm labor and the conventional and advanced procedures for early detection of PTB, including multi-omics and artificial intelligence/machine learning (AI/ML)- based approaches. It also discusses the principles of detecting various proteomic biomarkers based on lateral flow immunoassay and microfluidic chips, along with the commercially available point-of-care testing (POCT) devices and associated challenges. After briefing the therapeutic and preventive measures of PTB, this review summarizes with an outlook.

show abstract

Pregnancy associated plasma protein A: An indicator of adverse obstetric outcomes in a South India population

Cited by 6 publications

References 19 publications

Pregnancy-Associated Plasma Protein-A: Its Significance as a Single Biomarker for Adverse Obstetric Outcomes

Pregnancy-Associated Plasma Protein-A: Its Significance as a Single Biomarker for Adverse Obstetric Outcomes

High Frequency of Fetal Loss in Fetuses with Normal Karyotype and Nuchal Translucency ≥ 3 among the Iranian Pregnant Women

Recent Advances and Challenges in the Early Diagnosis and Treatment of Preterm Labor

Contact Info

Product

Resources

About